BUFFALO, N.Y., April 23, 2020 -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel.
Q4 2019 Athenex Inc Earnings Call
Q1 2020 Athenex Inc Earnings Call
BUFFALO, N.Y., April 29, 2020 -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel.
BUFFALO, N.Y., May 19, 2020 -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies.
After nearly a decade of steady stock returns, U.S. markets have hit a rough patch. U.S.-listed stocks, which hit record highs on February 19, have tumbled rather dramatically and quickly since the coronavirus, deemed as COVID-19, was uncovered in China. As has been widely covered in the press, it has since started to spread throughout the world.A few market pundits predict a lasting or sustainable hit to global economic growth. Largely as a precautionary measure, the U.S. Federal Reserve lowered interest rates by 50 basis points and stands ready with further rate cuts to prop up the economy. Certain industries, including travel-related and economically sensitive ones, could continue to struggle, but most others are projected to see a more limited downturn and a V-shaped recovery, or a quick bounce back to normal financial conditions.Downturns can also present buying opportunities for contrarian-minded investors. Investment firm Needham has recently been thinking along these lines and came out with a report of its best ideas on stocks that should rally when the spread of COVID-19 will stabilize, and eventually decline.We’ve taken three of Needham’s top picks and looked them up in the TipRanks database. These are investments that the Stock Screener tool reveals as “Strong Buy” analyst consensus rated and, more importantly, all three offer robust upside potential. Let’s take a closer look.Athenex Inc (ATNX)Starting with biotech. Needham's Chad Messer lists Athenex as his best idea once the COVID-19 situation settles down. The biggest near-term risk is that much of Athenex’s manufacturing capabilities reside in China, which is seeing rather severe coronavirus complications to its supply chain.Athenex has ambitions to become a global leader, hoping to bring innovative cancer treatments to the market and improve outcomes for patients. It has two lead drug candidates – a treatment for skin condition actinic keratosis, and an oral treatment for metastatic breast cancer. Both have Food and Drug administration (FDA) applications pending.According to Dr. Messer, “the overwhelming driver for ATNX remain NDA acceptance for its oral chemotherapy Oraxol, which we expect in 2Q.” In preparation for the expected release, Athenex management is building out its sales force and should start to see significant sales come in next year.Messer’s financial model projects a stellar 74% sales jump next year, reaching $150 million for the full year. However, profits aren’t expected for a few more years. As a result, the $30 price target that accompanies his Buy rating is based off of 5 times the 2025 sales estimate, discounted back to today, and implies 186% upside potential. (To watch Messer’s track record, click here)The stock is down 31% so far this year. This leaves significant room for upside once Oraxol starts hitting the marketplace. The company also has $161 million on the balance sheet, which is a nice cushion until sales start really coming in.With 100% Street support, the message is clear: ATNX is a Strong Buy. Should the $27.33 average price target be met, shares could be in for a 161% twelve-month gain. (See Athenex stock analysis on TipRanks)Mimecast (MIME)Needham analyst Alex Henderson, who covers networking and security firms, has pegged London, UK-based Mimecast Limited a compelling pick once the COVID-19 situation improves. In a recent report, he touted Mimecast as “the premiere company protecting against email-borne threats.”Specifically, Mimecast is an email and data security company that provides cloud security and risk management services. Its Mimecast Email Security services are built for threat protection, such as the threat from emails containing malicious links.The stock chart is far from pretty. The shares have fallen 22% so far this year and a much more severe 37% over the past month. Henderson attributes the severe drop to the fact that nearly half of revenue stems from international sources, including 29% from Europe where COVID-19 containment efforts have not been as effective as in the rest of the world.Mimecast could struggle to boost sales in the near-term. Henderson characterizes the firm’s sales approach as “high-touch” where travel restrictions could hamper the needed approach from the sales team. Henderson projects 17%-21% average annual sales growth over the next three to five years. He highlighted a couple of new products at the company’s recent investor day, including a browser isolation service targeted for email and web security, as well as a threat intelligence service that allows for the integration of third-party applications to enhance security offerings. Some compelling growth markets, for sure.Despite these myopic worries, the analyst maintains a Buy rating and price target of $65 per share, suggesting 91% upside potential from the current share price. (To watch Henderson’s track record, click here)What does the rest of the Street think? It turns out that other analysts are generally on the same page. With 9 Buy ratings vs 1 Hold received in the last three months, the word on the Street is that MIME is a Strong Buy. Not to mention the $60.10 average price target suggests 79% upside potential. (See Mimecast price targets and analyst ratings on TipRanks)Medallia Inc. (MDLA)In the software-as-a-service (SAAS) space, Needham analyst Scott Berg has pegged San Francisco-based Medallia as his pick-to-click once COVID-19 complications subside. Medallia bills itself as a deep learning-based artificial intelligence technology that can analyze structured and unstructured data from signal fields in human, digital, and Internet of Things interactions. It’s known as experience management.Medallia will produce positive operating cash flow later this year, according to his valuation model. Until profit targets improve, the analyst estimates an enterprise value to revenue multiple of 14 times off 2021 sales of $480 million.The share-price decline of 32% has also been severe this calendar year. That being said, sales growth projections are impressive and the company will be profitable well ahead of target if it reaches these lofty top-line expectations.Berg maintains a Buy rating on Medallia, and his $45 price target is based on average projected sales growth of above 20% in each of at least the next three years. The price target also suggests the stock can more than double from the current share price of $21.29. (To watch Berg’s track record, click here)Looking at the consensus breakdown, 3 out of 3 analysts that have published a recent review see the stock as a Buy, making the consensus rating a Strong Buy. At $46.67, the average price target puts the upside potential at 130%. (See Medallia stock analysis on TipRanks)
BUFFALO, N.Y. (AP) — Athenex Inc. (ATNX) on Thursday reported a loss of $19.4 million in its first quarter.
Regulatory filings for tirbanibulin ointment for actinic keratosis submitted to both FDA and EMA Oral Paclitaxel NDA submission is on track 2020 product sales guidance.
BUFFALO, N.Y., April 09, 2020 -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel.
Pomerantz LLP is investigating claims on behalf of investors of Athenex, Inc. (“Athenex” or the “Company”) (ATNX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Athenex and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Athenex (ATNX) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Shares of Athenex (NASDAQ:ATNX) fell 4.8% after the company reported Q1 results.Quarterly Results Earnings per share were up 54.72% year over year to ($0.24), which missed the estimate of ($0.17).Revenue of $46,935,000 up by 85.46% year over year, which beat the estimate of $32,860,000.Guidance Athenex hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.Conference Call Details Date: May 07, 2020View more earnings on ATNXTime: 09:00 AM ETWebcast URL: http://public.viavid.com/player/index.php?id=139326Recent Stock Performance 52-week high: $21.1152-week low: $5.63Price action over last quarter: down 20.87%Company Overview Athenex Inc is a global biopharmaceutical company. It is dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer. The company's operating segment includes the Oncology Innovation Platform; Global Supply Chain Platform and Commercial Platform. It generates maximum revenue from the Commercial Platform segment. Commercial Platform segment includes APD, which focuses on the manufacturing, distribution, and sales of specialty pharmaceuticals. Geographically, it derives a majority of revenue from the United States and also has a presence in Spain; Austria; India; China; the United Kingdom and Other foreign countries.See more from Benzinga * ChannelAdvisor: Q1 Earnings Insights * GasLog Partners: Q1 Earnings Insights * Recap: Chimerix Q1 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the m…
ATNX earnings call for the period ending March 31, 2020.
Athenex (ATNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This morning, we are joined by Dr. Johnson Lau, Chief Executive Officer; Mr. Jeff Yordon, Chief Operating Officer; Dr. Rudolf Kwan, Chief Medical Officer; Mr. Randoll Sze, Chief Financial Officer; and Mr. Tim Cook, Senior VP, Global Commercial Oncology, who will be available to answer questions after the prepared remarks. With that, I'll turn the call over to Johnson for introductory comments.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the m…
NEW YORK, NY / ACCESSWIRE / May 8, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Athenex, Inc. ("Athenex" or "the Company") ...
Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today provides an update on the Company’s operations in light of the recent declaration of the coronavirus outbreak a pandemic. Athenex’s operational plans continue to remain on track and the Company’s current assessment is that the NDA submission for Oral Paclitaxel and pre-launch preparations for Oral Paclitaxel and tirbanibulin ointment should not be impacted. In addition, the Company’s interactions with the U.S. FDA and other regulatory authorities currently remain on schedule.
As of late, it has definitely been a great time to be an investor in Athenex, Inc. (ATNX).
Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that the U.S. Food and Drug Administration (FDA) has completed its filing review and determined that the Company’s New Drug Application (NDA) for tirbanibulin ointment (formerly known as KX2-391 or KX-01 ointment) for the treatment of actinic keratosis (AK) is sufficiently complete to permit a substantive review. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of December 30, 2020.
Athenex (ATNX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Athenex (ATNX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Athenex (ATNX) delivered earnings and revenue surprises of -14.29% and 46.90%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?